CORCEPT THERAPEUTICS INC

Corcept insider buying signals confidence in its GR‑II obesity therapy, as CEO William Guyer’s 2026 trades hint at future upside amid a competitive market and clinical progress.

Corcept Therapeutics insider trades reveal portfolio rebalancing, not distress, amid rising social‑media buzz—watch leadership moves for future growth signals.

James Wilson’s $0.00 sale of 28,000 Corcept shares shows insider tactical rebalancing amid a 15% month‑to‑date dip; investors should watch for future moves that could signal company milestones.

Insider buying by Corcept Therapeutics’ owner signals confidence despite FDA and legal headwinds, offering investors a stabilizing signal amid market volatility.

Corcept Therapeutics insiders buy 1.18 M options, boosting confidence amid a 41% share decline and pending fraud lawsuit.

Corcept insider trades reveal strategic confidence amid earnings miss – James Wilson buys at $3.88, sells at $36.48, signalling liquidity strategy and voting power consolidation for future option exercises and long‑term growth.